Walter M. Stadler to Histone Deacetylase Inhibitors
This is a "connection" page, showing publications Walter M. Stadler has written about Histone Deacetylase Inhibitors.
Connection Strength
0.164
-
Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium. Cancer. 2009 Dec 01; 115(23):5541-9.
Score: 0.083
-
Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC). Ann Oncol. 2010 Jan; 21(1):109-13.
Score: 0.081